Hospira Issues A Voluntary Nationwide Recall

On May 4th, 2021, Hospira—a Pfizer company, issued a voluntary nationwide recall to lot DN9185 for potential presence of visible particles.  This drug product is a sterile water for injectables and is used to dilute or dissolve drugs for injection.

Risks to patients are rare, but could potentially conclude anaphylaxis, fever, gastrointestinal disturbances, vein irritation, localized vein inflammation, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli and infarction. Hospira made sure to notify all wholesalers, distributers and hospitals who received this product from October to December 2020 and arranged for return of this recalled product.  There has yet to be any reports of patients having reactions to this product.

Data tracking, workflow, qualifications and integrity are all things InQuest Science’s Identifier Software focuses on.  This recall could have been prevented and tracked sooner if data information was imported on the Identifier Software.

Read the full recall on fda.gov

Comments are closed.